Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

A Prospective, Open-labelled, Non-controlled Observational Study to Assess Patient Satisfaction, Physician Acceptability and Safety of Mixtard® 30 NovoLet® for the Treatment of Diabetes Mellitus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01492218

Enrollment

1330

Registered

2011-12-14

Start date

2004-03-15

Completion date

2004-08-30

Last updated

2017-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.

Interventions

DRUGbiphasic human insulin 30

Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diabetes mellitus (type 1 or type 2) * Patient not presently using Mixtard® 30 NovoLet®

Design outcomes

Primary

Measure	Time frame
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score	—

Secondary

Measure	Time frame
Adverse events	—
Technical complaints of NovoLet® device	—

Countries

Philippines

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026